---
schema_version: "secwatch.filing_event.v1"
accession: "0001217234-26-000052"
form_type: "8-K/A"
ticker: "CDNA"
cik: "0001217234"
company_name: "CareDx, Inc."
filed_at: "2026-09-16T20:06:13+00:00"
generated_at: "2026-09-16T20:07:20.863725+00:00"
event_type: "m_and_a"
sentiment: "negative"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# CareDx files Naveris 2025 financials: revenue $34.3M, net loss $3.9M, going concern doubt

## Summary
- Naveris FY2025 revenue $34.337M; net loss $3.882M; accumulated deficit $65.049M.
- Substantial doubt about going concern; recurring operating losses and negative operating cash flow.
- Cash and equivalents $15.401M plus restricted cash $0.890M at Dec 31, 2025.
- Naveris is commercial-stage precision oncology; NavDx TTMV-HPV DNA test for viral-induced cancers.

## SEC filing metadata
- accession: 0001217234-26-000052
- form_type: 8-K/A
- ticker: CDNA
- cik: 0001217234
- company_name: CareDx, Inc.
- filed_at: 2026-09-16T20:06:13+00:00
- event_type: m_and_a
- sentiment: negative
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 9.01, 2.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1217234/000121723426000052/0001217234-26-000052-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1217234/000121723426000052/cdna-20260630.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001217234-26-000052
- JSON: https://secwatch.observer/filing/0001217234-26-000052.json
- Plain text: https://secwatch.observer/filing/0001217234-26-000052.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.